Literature DB >> 27862893

Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis.

S Sobhy1, Zoe Babiker2,3, J Zamora1,4,5, K S Khan1,4, H Kunst6.   

Abstract

BACKGROUND: There is a dearth of data on the clinical features and outcomes of active tuberculosis (TB) in pregnancy. Studies have shown varied results and the relationship between TB and adverse pregnancy outcomes remains unclear.
OBJECTIVES: We conducted a systematic review and meta-analysis to evaluate pregnancy outcomes associated with TB. SEARCH STRATEGY: Major databases were searched from inception until December 2015 without restrictions using the terms: 'TB', 'pregnancy', 'maternal morbidity', 'mortality' and 'perinatal morbidity', 'mortality'. SELECTION CRITERIA: We included studies that compared the outcomes of pregnant women with and without active TB. DATA COLLECTION AND ANALYSIS: We computed odds ratios for maternal and perinatal complications, and pooled them using a random effects model. We assessed for heterogeneity using chi-squared tests and evaluated its magnitude using the I2 statistic. We used the Newcastle-Ottawa scale for quality assessment. MAIN
RESULTS: Thirteen studies, including 3384 pregnancies with active TB and 119 448 without TB were included. Compared with pregnant women without TB, pregnant women with active TB was associated with increased odds of maternal morbidity [odds ratio (OR) 2.8, 95% CI 1.7-4.6; I2  = 60.3%], anaemia (OR 3.9, 95% CI 2.2-6.7; I2  = 29.8%), caesarean delivery (OR 2.1, 95% CI 1.2-3.8; I2  = 61.1%), preterm birth (OR 1.7, 95% CI 1.2-2.4; I2  = 66.5%), low birth weight (OR 1.7, 95% CI 1.2-2.4; I2  = 53.7%), birth asphyxia (OR 4.6, 95% CI 2.4-8.6; I2  = 46.3), and perinatal death (OR 4.2, 95% CI 1.5-11.8; I2  = 57.2%). AUTHOR'S
CONCLUSION: Active TB in pregnancy is associated with adverse maternal and fetal outcomes. Early diagnosis of TB is important to prevent significant maternal and perinatal complications. TWEETABLE ABSTRACT: Active tuberculosis in pregnancy is associated with adverse maternal and perinatal outcomes.
© 2016 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Active; maternal; perinatal; pregnancy outcomes; tuberculosis

Mesh:

Year:  2016        PMID: 27862893     DOI: 10.1111/1471-0528.14408

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  27 in total

1.  Female genital tuberculosis presented with primary infertility and persistent CA-125 elevation: A case report.

Authors:  Qian Feng; Xiaoxia Hu; Jing Zhao; Jingyao Huang; Liling Liu
Journal:  Ann Med Surg (Lond)       Date:  2022-05-03

2.  Interferon Gamma Release Assay and Tuberculin Skin Test Performance in Pregnant Women Living With and Without HIV.

Authors:  Samantha R Kaplan; Jaclyn N Escudero; Jerphason Mecha; Barbra A Richardson; Elizabeth Maleche-Obimbo; Daniel Matemo; John Kinuthia; Grace C John-Stewart; Sylvia M LaCourse
Journal:  J Acquir Immune Defic Syndr       Date:  2022-01-01       Impact factor: 3.771

Review 3.  Tuberculosis in Pregnancy.

Authors:  Kathryn Miele; Sapna Bamrah Morris; Naomi K Tepper
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

4.  Tuberculosis during pregnancy in the United States: Racial/ethnic disparities in pregnancy complications and in-hospital death.

Authors:  Erika M Dennis; Yun Hao; Mabella Tamambang; Tasha N Roshan; Knubian J Gatlin; Hanane Bghigh; Oladimeji T Ogunyemi; Fatoumata Diallo; Kiara K Spooner; Jason L Salemi; Omonike A Olaleye; Kashif Z Khan; Muktar H Aliyu; Hamisu M Salihu
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

5.  Left lung hypoplasia with a right tuberculous pleural effusion after childbirth: A case report.

Authors:  Shan Lin; Wei Guan; CuoMao LaZhou; Yingqing Shi
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

6.  A Case of Miliary Perinatal Tuberculosis in a Preterm Newborn Infant Presenting as Peritonitis.

Authors:  Artsiom Klimko; Alienor Brandt; Maria-Iulia Brustan
Journal:  Cureus       Date:  2020-05-09

7.  Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency.

Authors:  Rosie Mngqibisa; Michelle A Kendall; Kelly Dooley; Xingye Shirley Wu; Cynthia Firnhaber; Helen Mcilleron; Jennifer Robinson; Yoninah Cramer; Susan L Rosenkranz; Jhoanna Roa; Kristine Coughlin; Sajeeda Mawlana; Sharlaa Badal-Faesen; David Schnabel; Ayotunde Omoz-Oarhe; Wadzanai Samaneka; Catherine Godfrey; Susan E Cohn
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 20.999

8.  Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.

Authors:  David W Haas; Rosie Mngqibisa; Jose Francis; Helen McIlleron; Jennifer A Robinson; Michelle A Kendall; Paxton Baker; Sajeeda Mawlana; Sharlaa Badal-Faesen; Francis Angira; Ayotunde Omoz-Oarhe; Wadzanai P Samaneka; Paolo Denti; Susan E Cohn
Journal:  Pharmacogenet Genomics       Date:  2022-01-01       Impact factor: 2.000

9.  Beyond Early Infant Diagnosis: Changing the Approach to HIV-Exposed Infants.

Authors:  Surbhi Modi; Laura N Broyles; Michele Montandon; Megumi Itoh; Boniface Ochanda; Agnes Langat; David Sullivan; Helen Dale
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.771

10.  Dengue in pregnancy and maternal mortality: a cohort analysis using routine data.

Authors:  Enny S Paixao; Katie Harron; Oona Campbell; Maria Glória Teixeira; Maria da Conceição N Costa; Mauricio L Barreto; Laura C Rodrigues
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.